# GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL)

> **NCT05518318** · PHASE3 · UNKNOWN · sponsor: **Guangzhou Gloria Biosciences Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Classic Hodgkin's Lymphoma
- Recurrent Classic Hodgkin Lymphoma
- Refractory Classic Hodgkin Lymphoma

## Interventions

- **DRUG:** GLS-010
- **DRUG:** Chemotherapy of Investigator's choice

## Key facts

- **NCT ID:** NCT05518318
- **Lead sponsor:** Guangzhou Gloria Biosciences Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09
- **Primary completion:** 2025-06
- **Final completion:** 2025-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05518318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05518318, "GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05518318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*